Administrative approaches and leveraged resources for NSBCC Pilot Projects and Trans Alliance Challenges is described. The goal of the Pilot Projects program is to further the vision of the NSBCC at two levels - broaden our impact and influence with the local oncology community, and accelerate our Project goals. The goal of our Trans-Alliance activities programs are to assemble the best possible teams for meeting trans-Alliance challenges - whether meeting those challenges involves a competition or a cooperation with other CCNEs. For pilot projects, the NSBCC is partnering with the Broad Center for Regenerative l /ledicine and Stem Cell Research (Broad CRM), and with the Jonsson Comprehensive Cancer Center (JCCC), to develop a pilot project program that is designed to outreach to the broader, local community of cancer researchers and clinical oncologists. The Broad CRM and JCCC are providing at least $60,000 direct costs to match the $70,000 direct costs committed from CCNE funding, and are providing assistance in pilot project solicitations, selection, and oversight. Criteria for the selection of pilot projects are outlined. For trans-Alliance challenges and related activities, an administrative program is outlined for deciding how the NSBCC will respond to specific challenges. All NSBCC investigators, by choosing to be a part of the NSBCC, are committed towards working towards successfully executing of trans Alliance challenges, and so, depending upon the nature of the challenge, our approach is to put together the best team possible to meet that challenge. NSBCC director Heath, in consultation with co-Directors Dr. Phelps and Dr. Hood, as well as the NSBCC Internal Review Council, provide for oversight and administration of the Pilot Projects and Trans-Aliance Activities. The NSBCC External Advisory Board provides review expertise on the success of our programs.
Pilot Projects within the NSBCC are designed to help us extend the influence of our nanotechnology solutions to cancer biology and cancer clinical care problems into the broader, local oncology community. This is accomplished via a careful selection process of the right Projects, and by finding institutional partners who share our vision, and who provide substantial funds to match the CCNE resources.
|Su, Yapeng; Shi, Qihui; Wei, Wei (2017) Single cell proteomics in biomedicine: High-dimensional data acquisition, visualization, and analysis. Proteomics 17:|
|Collins, Jeffrey; Waldmann, Christopher M; Drake, Christopher et al. (2017) Production of diverse PET probes with limited resources: 24 18F-labeled compounds prepared with a single radiosynthesizer. Proc Natl Acad Sci U S A 114:11309-11314|
|Turner, Kristen M; Deshpande, Viraj; Beyter, Doruk et al. (2017) Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543:122-125|
|Ghosh, Dhimankrishna; Funk, Cory C; Caballero, Juan et al. (2017) A Cell-Surface Membrane Protein Signature for Glioblastoma. Cell Syst 4:516-529.e7|
|Hong, Candice Sun; Graham, Nicholas A; Gu, Wen et al. (2016) MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep 14:1590-1601|
|Henning, Ryan K; Varghese, Joseph O; Das, Samir et al. (2016) Degradation of Akt using protein-catalyzed capture agents. J Pept Sci 22:196-200|
|Wei, Wei; Shin, Young Shik; Xue, Min et al. (2016) Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell 29:563-573|
|Poovathingal, Suresh Kumar; Kravchenko-Balasha, Nataly; Shin, Young Shik et al. (2016) Critical Points in Tumorigenesis: A Carcinogen-Initiated Phase Transition Analyzed via Single-Cell Proteomics. Small 12:1425-31|
|Ghosh, Dhiman; Ulasov, Ilya V; Chen, LiPing et al. (2016) TGF?-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme. Stem Cells 34:2276-89|
|Clark, Andrew J; Wiley, Devin T; Zuckerman, Jonathan E et al. (2016) CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc Natl Acad Sci U S A 113:3850-4|
Showing the most recent 10 out of 54 publications